Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma

Area of Science:

• Natural product chemistry
• Molecular pharmacology
• Cancer biology

Background:

• Deoxyelephantopin (ESD) is a natural compound with reported anti-cancer properties, including apoptosis potentiation and invasion inhibition.
• The specific molecular target of ESD has remained undisclosed, limiting a full understanding of its mechanism of action.

Purpose of the Study:

• To investigate the molecular target and mechanism of action of Deoxyelephantopin (ESD) in cancer cells.
• To elucidate the interaction between ESD and its potential protein targets at an atomic level.

Main Methods:

• Cell proliferation assays, apoptosis assays, and cell cycle analysis were performed on HeLa cancer cells.
• Biochemical and biophysical assays were used to identify and characterize the interaction of ESD with protein targets.
• Molecular docking and site-directed mutagenesis were employed to analyze the binding mode of ESD to PPARgamma.
• PPARgamma knockdown experiments were conducted to assess its role in ESD's anti-proliferative effects.

Main Results:

• ESD significantly inhibited the proliferation of various cancer cells and induced apoptosis and G2/M cell cycle arrest in HeLa cells.
• Biochemical and biophysical studies identified ESD as a specific partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).
• Molecular docking and mutagenesis revealed a distinct binding mode of ESD to PPARgamma compared to rosiglitazone.
• PPARgamma knockdown suggested that ESD's anti-proliferative effects are likely mediated through a PPARgamma-independent pathway.

Conclusions:

• ESD exhibits potent anti-cancer properties, including the inhibition of cancer cell proliferation and induction of apoptosis.
• While ESD interacts with PPARgamma as a partial agonist, its primary anti-cancer effects appear to be independent of this receptor.
• The study provides atomic-level insights into ESD/PPARgamma interactions and suggests potential alternative therapeutic targets for this natural compound.